Tucci, Francesca http://orcid.org/0000-0001-8798-8987
Frittoli, Marta
Barzaghi, Federica
Calbi, Valeria
Migliavacca, Maddalena
Ferrua, Francesca
Fumagalli, Francesca
Lorioli, Laura
Castagnaro, Laura
Facchini, Marcella
Fossati, Claudia
Zancan, Stefano
Massariello, Paola
Manfredini, Michele
Consiglieri, Giulia
Canarutto, Daniele
Recupero, Salvatore
Calzatini, Francesco
Casiraghi, Miriam
Darin, Silvia
Antonioli, Gigliola
Miniero, Roberto http://orcid.org/0000-0002-5716-4730
Fiori, Rossana
Silvani, Paolo
Zambelli, Matilde
Marktel, Sarah
Gattillo, Salvatore
Milani, Raffaella
Santoleri, Luca
Ciceri, Fabio
Biffi, Alessandra
Cicalese, Maria Pia
Bernardo, Maria Ester
Aiuti, Alessandro
Article History
Received: 9 November 2018
Revised: 15 March 2019
Accepted: 5 April 2019
First Online: 31 May 2019
Compliance with ethical standards
:
: Fondazione Telethon and San Raffaele Hospital developed gene therapy for ADA-SCID, WAS and MLD, for which GlaxoSmithKline (GSK) acquired their license. AA is the PI of the WAS and MLD clinical trials for gene therapy. ADA-SCID gene therapy (Strimvelis) was licensed to GSK in 2010 and received European marketing authorisation in 2016. These licenses were transferred to Orchard Therapeutics (OTL) in April 2018. The other authors declare that they have no conflict of interest.